Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update

Access this Article

Search this Article

Author(s)

    • KANEKO Shuichi
    • Department of Medical Oncology, Kyorin University School of Medicine
    • FURUSE Junji
    • Department of Medical Oncology, Kyorin University School of Medicine
    • NAKAMOTO Yasunari
    • Department of Gastroenterology, Graduate School of Medicine, Fukui University
    • ONCHI Morikazu
    • Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University
    • SHIOTA Goshi
    • Division of Molecular and Genetic Medicine, Tottori University Graduate School of Medicine
    • YOKOSUKA Osamu
    • Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University
    • SAKAIDA Isao
    • Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine
    • TAKEHARA Tetsuo
    • Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine
    • UENO Yoshiyuki
    • Department of Gastroenterology, Tohoku University Graduate School of Medicine
    • HIROISHI Kazumasa
    • Division of Gastroenterology, Department of Medicine, Showa University School of Medicine
    • NISHIGUCHI Shuhei
    • Division of Hepatobiliary and Pancreatic Diseases, Department of Internal Medicine, Hyogo College of Medicine
    • MORIWAKI Hisataka
    • Department of Gastroenterology, Gifu University Graduate School of Medicine
    • YAMAMOTO Kazuhide
    • Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine
    • SATA Michio
    • Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine
    • MIYAYAMA Shiro
    • Department of Diagnostic Radiology, Fukuiken Saiseikai Hospital
    • IMAI Yukinori
    • Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University

Abstract

The "Guideline on the Use of New Anticancer Drugs for the Treatment of Hepatocellular Carcinoma" was prepared by the Study Group on New Liver Cancer Therapies established by the "Research Project on Emergency Measures to Overcome Hepatitis" under the auspices of the Health and Labour Sciences Research Grant. The Guideline brings together data collected by the Study Group on the use and incidence of adverse events in 264 patients with advanced hepatocellular carcinoma (HCC) treated using sorafenib and in 535 patients with advanced HCC treated using miriplatin at 16 participating institutions up until 22 December 2010, as well as referring to the published studies, academic presentations, and reports from the private sector. The aim of this Guideline is to facilitate understanding and current thinking regarding the proper usage of new anticancer drugs towards actual use in therapy. In terms of the format, the Guideline presents "clinical questions" on issues pertaining to medical care, makes "recommendations" on diagnosis and treatment in response to each of these clinical questions, and provides a rationale for these recommendations in the form of "scientific statements". © 2012 The Japan Society of Hepatology.

Journal

  • Hepatology Research

    Hepatology Research 42(6), 523-542, 2012-06-01

    Wiley-Blackwell

References:  35

Cited by:  2

Codes

  • NII Article ID (NAID)
    10031144267
  • NII NACSIS-CAT ID (NCID)
    AA11140867
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    13866346
  • Data Source
    CJP  CJPref  IR 
Page Top